
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Pharmaceutical Preparations · market cap $6.0B · as of 2026-06-29
Research and calibrated estimates, not financial advice — verify before acting.
No upcoming catalysts in our calendar.
| Asset | Phase | Indication |
|---|---|---|
| Brexpiprazole | Phase 3 | Sleep Disturbances |
| Lu AG13909 | Phase 2 | Cushing's Disease |
| Zicronapine | Phase 2 | Schizophrenia |
| Azilect® | Phase 3 | Parkinson's Disease |
| Gaboxadol | Phase 3 | Primary Insomnia |
| Vortioxetine (Lu AA21004) | Phase 3 | Major Depressive Disorder |
| Duloxetine | Phase 3 | Major Depressive Disorder |
| Lu AG09222 | Phase 2 | Migraine |
| Idalopirdine | Phase 3 | Alzheimer's Disease |
| Lu AE58054 | Phase 2 | Alzheimer's Disease |
| Olanzapine | Phase 3 | Schizophrenia |
| Vortioxetine | Phase 2 | Depressive Disorder |
| Eptinezumab | Phase 3 | Migraine |
| Sertindole | Phase 3 | Schizophrenia |
| Nalmefene | Phase 3 | Alcohol Dependence |
| Desmoteplase | Phase 3 | Stroke |
| Risperidone | Phase 3 | Schizophrenia |
| Lu AF82422 | Phase 2 | Multiple System Atrophy |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
See ProApproval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.